
EMCS vs PHAR
$EMCS vs $PHAR head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
EMCS vs PHAR: trend, levels and the market
One year to 2026-11-20, against the S&P 500 (+4.7%). Split-adjusted daily closes.
- ·EMCS is the weaker of the two on trend, below both its 50- and 200-day averages, while PHAR has held above one of them.
- ·Only EMCS beat the market over the past year, by 3.5%, while PHAR trailed the S&P 500 at +4.7% by 33.7%.
- ·The last month has flipped the order: PHAR leads over the month (+8.2% against -13.8%) even though EMCS leads over the year.
- ·EMCS has support 1.7% below at $36.35; PHAR has no tested support within 35% under its price.
- ·EMCS is within 2.7% of resistance at $37.99, a price where it has stalled before.
- ·PHAR is within 2.7% of resistance at $11.85, a price where it has stalled before.
Support and resistance are daily prices the stock has turned at three or more times, within 35% of the price. The loading zone is the nearby price where the heaviest volume traded. These describe where a stock has been, not where it will go. Not investment advice.
EMCS vs PHAR: the quick read
- ·EMCS is the larger company by market cap ($830M vs $817M).
- ·EMCS has been more active on our scanner (8 vs 5 alerts in 30 days).
- ·These sit in different industries (UNKNOWN vs Pharmaceutical Preparations), so they answer to different catalysts and a move in one says little about the other.
- ·Both stay busy on our scanner, 8 and 5 unusual-volume alerts over 30 days, so neither is the quiet one here.
- ·They are closely matched in size, within 2% of each other on market cap, which makes the rest of this table the interesting part.
- ·Both sit in the bottom quarter of their 52-week range, so this is a comparison of two names well off their highs.
- ·EMCS pays a dividend and PHAR does not, which usually means one is being held for income and the other for the move.
Objective differences only. Not investment advice.
Watching EMCS or PHAR? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing EMCS and PHAR on TheDesperateTrader.
- Is EMCS or PHAR the better stock?
- "Better" depends on your goal, and these two are not alike. EMCS is the larger company by market cap ($830M vs $817M). EMCS has been more active on our scanner (8 vs 5 alerts in 30 days). These sit in different industries (UNKNOWN vs Pharmaceutical Preparations), so they answer to different catalysts and a move in one says little about the other. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between EMCS and PHAR?
- The differences that matter: they are not in the same business - EMCS is unknown and PHAR is pharmaceutical preparations; they are similar in size ($830M vs $817M); they trade at very different share prices ($36.98 vs $11.54); EMCS sits at 21% of its 52-week range against 20% for PHAR; only EMCS pays a dividend; our scanner flagged EMCS 8 times in the last 30 days against 5 for PHAR. Everything above is measured from the latest completed session and SEC filings.
- Which of EMCS and PHAR is more active right now?
- Right now EMCS is at about 0.0x its normal volume and PHAR is at about 0.8x, so PHAR is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is EMCS or PHAR in the stronger trend?
- EMCS is below its 50-day average of $44.42 and below its 200-day average of $43.32; PHAR is above its 50-day average of $11.06 and below its 200-day average of $13.31. PHAR leads 3 of the 5 measures on this page (1 year, vs S&P 500, 3 months, 1 month, trend). A trend is where a stock has been, not a forecast, and nothing here is investment advice.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading EMCS or PHAR? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysExplore the market
Free, live market tools. No account required to look.